Eli Lilly (LLY): FY25 Q2 earnings call, Aug 7, 2025
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Aug 7, 2025 earnings call (FY25 Q2). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
9 matches for “LillyDirect”; 5 quoted, at least 25 words apart.
…most commonly used medicines. We operate a direct-to-consumer model at scale through LillyDirect, which provides more affordable access to Lilly medicines. This includes our leading…
…taking Zepbound. We recently launched the 12.5- and 15-milligram single-use vials in LillyDirect. All doses of Zepbound are not available in the vial presentation. While…
Congrats on the quarter. Just going back to channel dynamics. On the LillyDirect channel, clearly, Zepbound growth has been getting a lot of momentum with…
Okay. Thanks for the question, Asad. Lucas, you want to give some commentary on the LillyDirect sort of evolution and outlook from here?
…would be a gradual progression on the employer access. We see the LillyDirect as an option to bridge that, right, as a hedge strategy to…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2025-08-07:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2025-08-07:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP